The New CHEST Guidelines on Antithrombotic Therapy for Atrial Fibrillation Should Consider Recent Data on Rivaroxaban

被引：1

作者：

Kim, Young-Hoon ^{[1
]}

Shim, Jaemin ^{[1
]}

Tsai, Chia-Ti ^{[2
]}

Wang, Chun-Chieh ^{[3
]}

Vilela, Gilbert ^{[4
]}

Muengtaweepongsa, Sombat ^{[5
]}

Kurniawan, Mohammad ^{[6
]}

Maskon, Oteh ^{[7
]}

Hsu, Li Fern ^{[8
]}

Thang Huy Nguyen ^{[9
]}

Sim, Kenneth ^{[10
]}

Camm, A. John ^{[11
,12
]}

机构：

[1] Korea Univ, Med Ctr, Seoul, South Korea

[2] Natl Taiwan Univ Hosp, Taipei, Taiwan

[3] Chang Gung Univ, Chang Gung Mem Hosp, Taoyuan, Taiwan

[4] Philippine Heart Ctr, Quezon City, Philippines

[5] Thammasat Univ, Stroke Excellence Ctr, Fac Med, Pathum Thani, Thailand

[6] Univ Indonesia, Dept Neurol, Cipto Mangunkusumo Natl Hosp, Fac Med, Jakarta, Indonesia

[7] Natl Univ Malaysia, Dept Med, Med Ctr, Kuala Lumpur, Malaysia

[8] Mt Elizabeth Novena Specialist Ctr, Novena Heart Ctr, Singapore, Singapore

[9] Pham Ngoc Thach Med Univ, Dept Neurol, Ho Chi Minh City, Vietnam

[10] Bayer South East Asia Pte Ltd, Singapore, Singapore

[11] Univ London, Cardiol Clin Acad Grp St Georges, London, England

[12] Imperial Coll, London, England

来源：

关键词：

ANTAGONIST ORAL ANTICOAGULANTS; STROKE PREVENTION; WARFARIN; DABIGATRAN; ASIANS;

D O I：

10.1016/j.chest.2019.03.036

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：1309 / 1311

页数：4

共 50 条